Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 0.55 |
| ▸ | EGFR | P00533 | 8/20 | 0.53 |
| ▸ | NQO2 | P16083 | 1/20 | 0.53 |
| ▸ | FECH | P22830 | 1/20 | 0.53 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.53 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23957561 | 0.92 | ERBB2 (0.54) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24945224 | 0.92 | ERBB2 (0.56) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24945583 | 0.91 | ERBB2 (0.56) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL27197212 | 0.91 | ERBB2 (0.56) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24174243 | 0.90 | ERBB2 (0.55) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24173696 | 0.90 | ERBB2 (0.53) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24173711 | 0.89 | ERBB2 (0.56) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL23747164 | 0.89 | ERBB2 (0.54) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL30576158 | 0.89 | ERBB2 (0.54) | ERBB2EGFRNQO2FECHMYH14 | |
| SCHEMBL24945219 | 0.89 | ERBB2 (0.55) | ERBB2EGFRNQO2FECHMYH14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374021-A1 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374021-A1 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2023-11-23 | — | — | US | disclosed |
| US-20210332054-A1 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-10-28 | — | — | US | disclosed |
| WO-2021213800-A1 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374021-A1 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | ERBB2, ERBB3, ERBB4 | ERBB2 1/4885EGFR 4/4885NQO2 467/4885 |
| US-20210332054-A1 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | ERBB2, ERBB3, ERBB4 | ERBB2 1/4885EGFR 4/4885NQO2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.